Unresectable Intrahepatic Cholangiocarcinoma Clinical Trial
Official title:
A Pilot Study of Neoadjuvant Therapy With Gemcitabine and Cisplatin in Patients With Resectable or Unresectable Intrahepatic Cholangiocarcinoma
This research study is evaluating the use of radiation therapy in combination with chemotherapy as a possible treatment for intrahepatic cholangiocarcinoma, a rare form of gastrointestinal cancer.
This study is to assess the possibility of using radiation therapy to treat intrahepatic
cholangiocarcinoma. Radiation therapy is used for many other types of malignancies, but its
use for the treatment of this form of gastrointestinal cancer has been limited. This
treatment is still being studied as research doctors are trying to find out more about its
use in the treatment of your form of gastrointestinal cancer. Short course photon radiation
and short course proton beam radiation therapies are FDA (U.S. Food and Drug Administration)
approved radiation delivery systems. This study will also test the safety of neoadjuvant
chemotherapy versus adjuvant chemotherapy. Neoadjuvant therapy is treatment given as a first
step to shrink a tumor before the main treatment, which is usually surgery, is given.
Adjuvant therapy is additional cancer treatment given after the primary treatment to lower
the risk that the cancer will come back.
The current standard of care for patients with intrahepatic cholangiocarcinoma is to offer
surgical resection to all patients who have resectable disease and are able to tolerate a
major surgical intervention.
The study interventions involved this trial may include one or more of the following:
- Chemotherapy (Gemcitabine and Cisplatin)
- Surgical Resection and Lymphadenectomy
- Radiation Therapy
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03942328 -
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04175912 -
Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver
|
Phase 2 | |
| Recruiting |
NCT06058663 -
Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma
|
Phase 1 | |
| Recruiting |
NCT05738057 -
Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and PD1 Antibody in Advanced and Unresectable Intrahepatic Cholangiocarcinoma
|
Phase 2 | |
| Terminated |
NCT02994251 -
A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients With Advanced Intra-Hepatic Cholangiocarcinoma
|
Phase 2 | |
| Completed |
NCT01648023 -
Drug-Eluting Bead, Irinotecan Therapy for Unresectable Intrahepatic Cholangiocarcinoma w/Concomitant Gemcitabine and Cisplatin or Carboplatin
|
Phase 2 | |
| Recruiting |
NCT05564403 -
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
|
Phase 2 | |
| Active, not recruiting |
NCT03768414 -
Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers
|
Phase 3 | |
| Completed |
NCT04301778 -
Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT04251715 -
mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma
|
Phase 2 |